Xiao Lin
Director/Board Member at Beijing Falikang Pharmaceutical Co. Ltd.
Network origin in Xiao Lin first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Beijing Falikang Pharmaceutical Co. Ltd.
 Beijing Falikang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., Beijing Falikang Pharmaceutical Co. Ltd. is a pharmaceutical company that manufactures pharmaceutical products. Beijing Falikang Pharmaceutical Co. Ltd. is based in Beijing, China. Beijing Falikang Pharmaceutical Co. was acquired by FibroGen (China) Medical Technology Development Co. Ltd. on July 31, 2020 for $2.14 million. The Chinese company was founded in 2019.
4
| Subsidiary | Pharmaceuticals: Major | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Xiao Lin via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| FIBROGEN, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree | |
FibroGen (China) Medical Technology Development Co. Ltd.
 FibroGen (China) Medical Technology Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd. is a biomedical technology company based in Beijing, China. FibroGen () is dedicated to developing new mechanisms of action or "best-in-class" innovative drugs and medical devices to meet the unmet clinical needs of Chinese patients. The Chinese company also provides a platform to report adverse events related to FibroGen roxadustat products. The company was founded in 2011. Christine Chung L. has been the CEO of the company since 2019. | Pharmaceuticals: Major | Chief Executive Officer | |
| FibroGen International (Hong Kong) Ltd. | Director/Board Member | ||
| FibroGen International (Cayman) Ltd. | Director/Board Member |
Statistics
International
| United States | 4 |
| China | 2 |
| Hong Kong | 2 |
| Cayman Islands | 2 |
Sectoral
| Health Technology | 3 |
| Technology Services | 2 |
| Consumer Services | 2 |
Operational
| Director/Board Member | 5 |
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
| Chief Executive Officer | 1 |
| Chairman | 1 |
Most connected contacts
| Insiders | |
|---|---|
| Christine Chung L. | 7 |
| Joseph Watson | 1 |
| Ai Min Fu | 1 |
| Lu Jin | 1 |
- Stock Market
- Insiders
- Xiao Lin
- Company connections
